Solganal is a pharmaceutical drug that is classified as an immunosuppressant and is commonly used in the treatment of rheumatoid arthritis. Its generic name is aurothioglucose, and it is administered by intramuscular injection.
Solganal works by suppressing the immune response in the body, which helps to reduce the symptoms associated with autoimmune diseases such as rheumatoid arthritis. This drug specifically decreases the activity of certain immune cells and reduces the production of inflammatory substances, thereby alleviating joint pain, swelling, and stiffness associated with rheumatoid arthritis.
The dosage and administration of Solganal may vary depending on the severity of the condition and the individual patient's response to the treatment. It is typically used in combination with other medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or disease-modifying antirheumatic drugs (DMARDs), to achieve optimal therapeutic effects.
As with any medication, Solganal carries certain risks and potential side effects. Common side effects may include skin rash, stomach upset, and mouth sores. More serious side effects could include kidney problems, blood disorders, or allergic reactions. Regular monitoring of blood parameters and close supervision by a healthcare professional are necessary during Solganal treatment.
It is important to note that Solganal should not be used during pregnancy or breastfeeding, as it may harm the developing fetus or pass into breast milk. Therefore, it is crucial to discuss potential risks and benefits with a healthcare provider before starting Solganal therapy.
